Improved risk stratification and predictive biomarkers of treatment response are needed for non-muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC.
(UroToday.com) In this presentation, Dr. Tannir presented data of a randomized placebo-controlled trial of cabozantinib without the glutaminase inhibitor telaglenastat in patients with advanced renal cell carcinoma (RCC) who have previously progressed on immune checkpoint blockade or anti-angiogenic therapies. The potential benefit of glutaminase inhibitors in cancer is predicated on data suggesting that tumor cells […]
(UroToday.com) As part of the 2021 American Society of Clinical Oncology Annual Meeting, a session entitled “Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?”. Within this session, Dr. Brandon Mahal discussed genomic disparities in prostate cancer.
(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis (including abiraterone acetate and enzalutamide), there is an ongoing interest to explore and develop a novel therapeutic approach […]
(UroToday.com) The Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2021 annual meeting included a metastatic castrate-resistant prostate cancer (mCRPC) session and a presentation by Dr. Robert Flavell discussing beta-emitting PSMA molecular radiotherapy in mCRPC. Dr. Flavell notes that there is much excitement around PSMA radioligand therapy, which is a theranostic treatment strategy that leverages […]
(UroToday.com) The Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2021 annual meeting included a metastatic castrate-resistant prostate cancer (mCRPC) session and a presentation by Dr. Hossein Jadvar discussing alpha-emitting PSMA molecular radiotherapy in mCRPC. Dr. Jadvar notes that the lethal potency of alpha particles includes:
(UroToday.com) In this session, Dr. Andrea Apolo reviewed the rationale behind combination therapies for management in advanced renal cell carcinoma (RCC). Over the past 15 years, treatment for advanced RCC has focused on anti-VEGF molecules based on knowledge of the complex signaling interplay between VHL, hypoxia-inducible factors, and VEGF. More recently, it has become clear that […]
Charles Ryan: Hello from ASCO 2021. Chuck Ryan here from the University of Minnesota. I’m joined by colleague Tom Beer from Oregon Health Sciences University, where he is a Professor of medicine and the Grover Bagby Chair of Prostate Cancer Research. Dr. Beer was part of a team and presented abstract 5013 results of an […]
(UroToday.com) Dr. Robert Motzer presented health-related quality of life (HRQoL) data from the phase 3 CLEAR study that evaluated the tyrosine kinase inhibitor lenvatinib in combination with either pembrolizumab or everolimus relative to sunitinib as first-line therapy advanced renal cell carcinoma (RCC). The combination of lenvatinib and pembrolizumab (len/pem) demonstrated significant improvement in overall survival, progression-free […]
(UroToday.com) Late relapses of germ cell tumors are defined as disease relapse more than two years after treatment. Monitoring per NCCN guidelines includes a combination of imaging along with a physical exam and tumor markers from years 3-5 post-diagnosis and an annual physical exam with tumor markers after 5 years. A previous study1 suggested that […]
